Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications

Area of Science:

• Oncology
• Endocrinology
• Bone Metabolism

Background:

• Osteopenia and osteoporosis are common long-term complications of anti-neoplastic therapies.
• Cancer treatment-induced bone loss (CTIBL) elevates fracture risk in oncologic patients, diminishing quality of life.
• Multiple cancer treatments, including hormone therapy, chemotherapy, radiotherapy, and tyrosine kinase inhibitors, can disrupt bone remodeling.

Purpose of the Study:

• To highlight the significance of identifying cancer patients at risk for CTIBL.
• To emphasize the need for early diagnosis and intervention strategies for CTIBL.
• To underscore the importance of managing bone metabolism during anti-tumor treatments.

Main Methods:

• Review of existing literature on cancer treatment-induced bone loss.
• Analysis of mechanisms by which various anti-cancer therapies affect bone remodeling.
• Identification of risk factors associated with CTIBL.

Main Results:

• Hormone therapy is a primary contributor to CTIBL, but other agents also play a role.
• Chemotherapies, radiotherapy, and tyrosine kinase inhibitors can deregulate bone remodeling through diverse pathways.
• CTIBL leads to a higher incidence of fractures in cancer patients compared to the general population.

Conclusions:

• Early identification of patients susceptible to CTIBL is essential for effective management.
• Interventions for CTIBL should encompass lifestyle modifications and pharmacological approaches.
• Preventing bone metabolism failure during cancer treatment is critical for patient outcomes and quality of life.